YMC America

YMC America is a prominent player in the biotechnology, life sciences, and pharmaceutical industries, specializing in the manufacturing of chromatography and downstream technologies. With over 40 years of experience, the company has established itself as a leader in the field, delivering standard and custom GMP scale systems known for their productivity gains, reproducibility, flexibility, and efficiency. In 2018, YMC Corporation expanded its portfolio by acquiring the LEWA Bioprocess Group, followed by the partnership with ChromaCon AG in 2019, enhancing its capabilities in continuous chromatography. YMC America's offerings are designed to meet the stringent requirements of the industry, complying with standards such as BPE, cGMP, GAMP, and 21 CFR under ISO 9001:2015 QMS. The company's expertise extends to designing, automating, and building downstream operations, including chromatography, buffer in-line dilution, caustic dilution, formulation and in-line blending systems, biosynthesis systems, and filtration technologies. The acquisition of ChromaCon AG has further strengthened YMC America's position, enabling the incorporation of advanced multi-column chromatography systems and the licensing of technology for the production of simulated moving bed (SMB) systems. Additionally, strategic partnerships with field services experts like ATG ensure exceptional global field support for the company's offerings. Having a workforce of over 500 employees and a 40+ year history, YMC America leverages its extensive experience and diverse expertise to simplify communications with clients, offering integrated services as a single source solution provider. With its solid track record and strategic growth initiatives, YMC America presents an attractive opportunity for potential investors in the biopharmaceutical manufacturing sector.